AAPL - After A Sensational 2018 BioTelemetry Seems To Be Losing Momentum
BioTelemetry (BEAT) specialises in the sale and distribution of cardiac monitoring equipment. It is a market leader having acquired its biggest rival, LifeWatch, in 2017.
Whilst the company's financials are solid, its overall market set for growth, and its aim to diversify into other markets such as remote data monitoring and glucose and diabetes management is praiseworthy, I would argue that a recent tie-up with Apple Health has over-inflated the share price.
The partnership, which helped Apple (AAPL) test the heart monitoring functionality of its smartwatches, raised prospects of a possible